Beta thalassemia minor—also known as beta thalassemia trait or B thalassemia—is a blood disorder. It lowers your blood’s level of hemoglobin, an iron-containing protein in red blood cells ...

Thalassemia remains a pressing health issue in India, with the country bearing a significant burden of this hereditary disorder. Despite advancements in treatment, the condition continues to ...

AAPI Nexus: Asian Americans and Pacific Islanders, Policy, Practice and Community Vol. 4, No. 2, Summer/Fall 2006 Thalassemia and Asian Americans: Living ... Thalassemia is a potentially ...

After a long struggle, and with the help of Frank Vella, a biochemist from Singapore University, we found that this child had thalassemia, an inherited blood disease that was thought at the time ...

An ad hoc committee of the National Academies of Sciences, Engineering, and Medicine will develop a strategic plan and blueprint for addressing thalassemia in the United States. In conducting its work ...

Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: I am Greek and have thalassemia minor. In general, my red blood cells are much smaller than typical ones ...

Discover top medications for 'treating Thalassemia'? This page compiles essential information on generic and brand-name drugs specifically used for Thalassemia treatment.Here, you can explore ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent beta-thalassemia in August 2022, and exagamglogene autotemcel (exa-cel; ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Dependency on future regulatory approvals for PYRUKYND and potential launches in thalassemia and sickle cell disease, which remain uncertain and could impact long-term revenue prospects.